Kao vs Sanofi

John Frieda Launches Campaign with Rossmann Partnership

Kao's haircare brand John Frieda is launching a new campaign titled "Generations by John Frieda" at the end of July, featuring testimonials Veronica Ferres and Lilly Krug in three video episodes. The campaign again teams the brand with the drugstore chain Rossmann as exclusive retail partner and uses Rossmann's retail-media and in‑store channels alongside social placements (Facebook, Instagram, TikTok), print (Gala) and digital integrations (Brigitte newsletter, banners on Rossmann's John Frieda page). Media planning and buying are handled by the Publicis agency Starcom. Kao emphasizes a strategy combining social-first content, influencer/creator collaborations and integrated retail activations to reach consumers along the full customer journey.

• Kao's John Frieda brand is launching the campaign "Generations by John Frieda" at the end of July 2026.
• The campaign features Veronica Ferres and Lilly Krug as testimonials across three video episodes.
• Rossmann is the exclusive retail partner for the Germany-wide in‑store implementation and supports the activation with its advertising and retail‑media channels.

6-K Financial Filing Analysis for Sanofi (2026-09-17)

On September 17, 2026, Sanofi submitted a Form 6-K filing with the U.S. Securities and Exchange Commission incorporating a press release dated September 14, 2026. The filing announces a new strategic partnership between Sanofi and Cheplapharm focused on mature medicines. This partnership reflects Sanofi's ongoing portfolio optimization strategy, allowing the company to streamline operations, monetize or efficiently manage established pharmaceutical assets, and reallocate focus and capital toward core growth drivers and innovative pipeline therapies.

• Sanofi entered into a strategic partnership with Cheplapharm focused on its mature medicines portfolio, originally announced via press release on September 14, 2026.
• The Form 6-K regulatory submission was formally executed and signed on September 17, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Agentic AI Transforming Pharma Marketing for Rare Diseases

This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.

• The pharma industry invests $2.6 billion on average to bring a new treatment to market, taking 12 to 15 years with a 10% success rate.
• Rare disease approvals now account for over 50% of FDA drug approvals, up from below 30% a decade ago.
• Sanofi is developing a 'lab-in-a-loop' using AI agents to compress discovery work from years to weeks.